Please use this identifier to cite or link to this item:
https://essuir.sumdu.edu.ua/handle/123456789/87802
Or use following links to share this resource in social networks:
Tweet
Recommend this item
Title | Atezolizumab (atezo) vs best supportive care (BSC) in stage II-IIIA NSCLC with high PD-L1 expression: Sub-analysis from the pivotal phase III IMpower010 study |
Authors |
Felip, E.
Altorki, N.K. Zhou, C. Vallieres, E. Vynnychenko, Ihor Oleksandrovych ![]() Akopov, A. Martinez-Marti, A. Chella, A. Bondarenko, I. Ursol, G. Levchenko, E. Kislov, N. Liersch, R. Belleli, R. McNally, V.A. Bennett, E. Gitlitz, B.J. Wakelee, H. |
ORCID |
http://orcid.org/0000-0002-2339-6509 |
Keywords |
IMpower010 present further analyses |
Type | Conference Papers |
Date of Issue | 2022 |
URI | https://essuir.sumdu.edu.ua/handle/123456789/87802 |
Publisher | Elsevier |
License | Creative Commons Attribution 4.0 International License |
Citation | Atezolizumab (atezo) vs best supportive care (BSC) in stage II-IIIA NSCLC with high PD-L1 expression: Sub-analysis from the pivotal phase III IMpower010 study / E. Felip, N. K. Altorki, C. Zhou et al. // Annals of Oncology. 2022. Volume 33, Issue S2. S 71. |
Abstract |
IMpower010 showed significant DFS benefit with atezo after adjuvant chemo in resected NSCLC (Felip Lancet 2021). At the interim DFS analysis, the significance boundary was crossed for the stage II-IIIA PD-L1 TC 1% population (stratified HR, 0.66; 95% CI: 0.50, 0.88), with greatest benefit in the PD-L1 TC 50%
subgroup (unstratified HR, 0.43; 95% CI: 0.27, 0.68). Here we present further analyses
in PD-L1 TC 50% stage II-IIIA NSCLC pts. |
Appears in Collections: |
Наукові видання (НН МІ) |
Views

1

1

1

1

1

7151

1

1

98376

44204

1660248

2198932

209
Downloads

1

1

1

1

1

859

4330

194581

1

1

2198930

582887

2198929

388736

1
Files
File | Size | Format | Downloads |
---|---|---|---|
Felip_et_al_Atezolizumab_2022.pdf | 156.83 kB | Adobe PDF | 5569260 |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.